Perspective Therapeutics, Inc. (CATX)Healthcare | Medical Devices | Seattle, United States | NYSE American
3.11 USD
-0.07
(-2.201%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.21 +0.10 (3.167%) ⇧ (Aug. 28, 2026, 7:33 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:20 a.m. EDT
This is a distressed biotech play with a fundamentally broken business model. The company is hemorrhaging cash, reporting negative revenue growth of over 70%, and burning through operating cash reserves at an alarming rate. Despite a 'strong buy' analyst recommendation driven by the potential of their radiopharma pipeline, the financial reality is dire: the stock trades at a negative forward P/E and has lost more than half its value over the last nine years. The market has correctly priced this as a value trap; the low price does not offer a margin of safety because the company is actively destroying shareholder value. The options market confirms this fear, with traders stacking heavy put protection expecting further declines. There is no catalyst here to reverse the multi-year downtrend without a miraculous turnaround in execution and capital preservation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.102499 |
| AutoARIMA | 0.152497 |
| AutoETS | 0.152498 |
| MSTL | 0.162474 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.060 |
| Excess Kurtosis | 0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.224 |
| Revenue per Share | 0.004 |
| Market Cap | 355,011,648 |
| Forward P/E | -3.05 |
| Beta | 1.80 |
| Previous Name | IsoRay, Inc. |
| Website | https://www.perspectivetherapeutics.com |
As of Aug. 22, 2026, 2:20 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in out-of-the-money puts relative to calls across all expirations. While there is some call volume at the $5.00 strike suggesting a speculative ceiling, the overwhelming weight of capital is in put options, indicating a consensus expectation of further price weakness rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.063252985 |
| Address1 | 2,401 Elliott Avenue |
| Address2 | Suite 320 |
| All Time High | 85.0 |
| All Time Low | 1.2 |
| Ask | 3.13 |
| Ask Size | 1,300 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 995,510 |
| Average Daily Volume3 Month | 1,654,126 |
| Average Volume | 1,654,126 |
| Average Volume10Days | 995,510 |
| Beta | 1.799 |
| Bid | 3.12 |
| Bid Size | 2,600 |
| Board Risk | 8 |
| Book Value | 2.839 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.11 |
| Current Ratio | 6.609 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.17 |
| Day Low | 3.075 |
| Debt To Equity | 1.224 |
| Display Name | Perspective Therapeutics |
| Earnings Timestamp | 1,786,392,000 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -121,186,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.008 |
| Enterprise To Revenue | 298.53 |
| Enterprise Value | 122,098,672 |
| Eps Current Year | -0.99173 |
| Eps Forward | -1.01963 |
| Eps Trailing Twelve Months | -1.3 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.1238 |
| Fifty Day Average Change | -0.013800144 |
| Fifty Day Average Change Percent | -0.0044177426 |
| Fifty Two Week Change Percent | -6.3252983 |
| Fifty Two Week High | 6.16 |
| Fifty Two Week High Change | -3.05 |
| Fifty Two Week High Change Percent | -0.49512988 |
| Fifty Two Week Low | 1.96 |
| Fifty Two Week Low Change | 1.1499999 |
| Fifty Two Week Low Change Percent | 0.5867346 |
| Fifty Two Week Range | 1.96 - 6.16 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,131,633,000,000 |
| Float Shares | 67,879,145 |
| Forward Eps | -1.01963 |
| Forward P E | -3.050126 |
| Free Cashflow | -69,425,624 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 163 |
| Fullday Change | -0.0700002 |
| Fullday Change Percent | -2.20126 |
| Fullday Price | 3.2085 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -95,770,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10802 |
| Held Percent Institutions | 0.85880995 |
| Implied Shares Outstanding | 114,151,663 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,718,582,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington. |
| Long Name | Perspective Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 355,011,648 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9934314 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -116,631,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 363,002,288 |
| Number Of Analyst Opinions | 15 |
| Open | 3.16 |
| Operating Cashflow | -93,067,000 |
| Operating Margins | -361.20987 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 206 676 0900 |
| Post Market Change | 0.09850001 |
| Post Market Change Percent | 3.1672032 |
| Post Market Price | 3.2085 |
| Post Market Time | 1,787,959,986 |
| Prev Name | IsoRay, Inc. |
| Previous Close | 3.18 |
| Price Eps Current Year | -3.135934 |
| Price Hint | 4 |
| Price To Book | 1.0954561 |
| Price To Sales Trailing12 Months | 867.99915 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.489 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.0700002 |
| Regular Market Change Percent | -2.20126 |
| Regular Market Day High | 3.17 |
| Regular Market Day Low | 3.075 |
| Regular Market Day Range | 3.075 - 3.17 |
| Regular Market Open | 3.16 |
| Regular Market Previous Close | 3.18 |
| Regular Market Price | 3.11 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 913,084 |
| Return On Assets | -0.22275 |
| Return On Equity | -0.39566 |
| Revenue Growth | -0.721 |
| Revenue Per Share | 0.004 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 114,151,663 |
| Shares Percent Shares Out | 0.2018 |
| Shares Short | 23,038,136 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 22,783,577 |
| Short Name | Perspective Therapeutics, Inc. |
| Short Percent Of Float | 0.241 |
| Short Ratio | 19.81 |
| Source Interval | 15 |
| State | WA |
| Symbol | CATX |
| Target High Price | 18.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 12.53333 |
| Target Median Price | 13.0 |
| Total Cash | 236,876,000 |
| Total Cash Per Share | 2.075 |
| Total Debt | 3,963,000 |
| Total Revenue | 409,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.54265 |
| Two Hundred Day Average Change | -0.4326501 |
| Two Hundred Day Average Change Percent | -0.12212612 |
| Type Disp | Equity |
| Volume | 913,084 |
| Website | https://www.perspectivetherapeutics.com |
| Zip | 98,121 |